Maze Therapeutics, Inc. $MAZE Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. increased its holdings in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) by 27.1% during the fourth quarter, HoldingsChannel reports. The fund owned 1,697,015 shares of the company’s stock after buying an additional 362,060 shares during the period. Vanguard Group Inc.’s holdings in Maze Therapeutics were worth $70,307,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Washington University grew its holdings in Maze Therapeutics by 33.3% during the fourth quarter. Washington University now owns 280,802 shares of the company’s stock worth $11,634,000 after acquiring an additional 70,121 shares during the period. Mass General Brigham Inc purchased a new stake in Maze Therapeutics during the fourth quarter worth $9,943,000. ArrowMark Colorado Holdings LLC purchased a new stake in Maze Therapeutics during the third quarter worth $14,135,000. Boothbay Fund Management LLC boosted its position in Maze Therapeutics by 365.9% during the third quarter. Boothbay Fund Management LLC now owns 351,875 shares of the company’s stock worth $9,124,000 after purchasing an additional 276,345 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in Maze Therapeutics by 171.8% during the third quarter. Rhumbline Advisers now owns 20,970 shares of the company’s stock worth $544,000 after purchasing an additional 13,256 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of analysts have commented on MAZE shares. HC Wainwright boosted their target price on Maze Therapeutics from $60.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, March 25th. Truist Financial decreased their target price on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating on the stock in a research report on Tuesday, April 14th. Wedbush boosted their target price on Maze Therapeutics from $43.00 to $58.00 and gave the stock an “outperform” rating in a research report on Monday, March 16th. Mizuho upgraded Maze Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 11th. Finally, Wall Street Zen downgraded Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 18th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $66.00.

Maze Therapeutics Stock Down 2.0%

Shares of NASDAQ:MAZE opened at $26.43 on Friday. The stock’s fifty day simple moving average is $33.83 and its 200-day simple moving average is $38.01. Maze Therapeutics, Inc. has a 52-week low of $8.24 and a 52-week high of $53.65. The company has a market capitalization of $1.32 billion, a P/E ratio of -10.45 and a beta of 2.50. The company has a quick ratio of 15.50, a current ratio of 17.88 and a debt-to-equity ratio of 0.11.

Maze Therapeutics (NASDAQ:MAZE) last released its earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The company had revenue of $20.00 million during the quarter. As a group, equities research analysts forecast that Maze Therapeutics, Inc. will post -2.59 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, SVP Amy Bachrodt sold 2,500 shares of the stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $29.44, for a total transaction of $73,600.00. Following the transaction, the senior vice president directly owned 12,965 shares in the company, valued at approximately $381,689.60. This represents a 16.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 30,000 shares of the stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $50.45, for a total value of $1,513,500.00. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 70,000 shares of company stock worth $2,955,775. 5.30% of the stock is owned by company insiders.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.